E. Sargent

In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration.

K. Pienta, R. Loberg, Natalie Mcgregor, 2007, Neoplasia.

Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.

Matthew J. Craig, K. Pienta, R. Loberg, 2007, Cancer research.

RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model

M. Day, W. Dougall, S. Daignault, 2008, The Prostate.

RANKLInhibition Is an EffectiveAdjuvant for Docetaxelin a ProstateCancerBone MetastasesModel

M. Day, W. Dougall, S. Daignault, 2008 .